Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
Healthcare
$4.34 -0.15%
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
52W Low $5.44High $9.42
Volume 0.47M
Average 0.09M
Balance Sheet
Inspect the capital base behind the business.
Assets
$166.13M
FY 2025 · Annual
+32.5% YoYLiabilities
$23.85M
FY 2025 · Annual
-11.7% YoYEquity
$142.28M
FY 2025 · Annual
+44.6% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 44.35M | 25.18M | 33.51M | 11.81M | 37.07M |
| Short-term Investments | 2.5M | 0 | 0 | 14.86M | 15.36M |
| Net Receivables | 1.82M | 15.61M | 16.84M | 29.15M | 36.95M |
| Inventory | 0 | 6.12M | 4.28M | 6.34M | 10.17M |
| Other Current Assets | 2.81M | 2.37M | 1.05M | 1.44M | 2.83M |
| Total Current Assets | 51.48M | 49.65M | 57.22M | 64.79M | 102.37M |
| Property, Plant & Equipment (Net) | 3.71M | 18.38M | 23.78M | 25.7M | 24.73M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 1.86M | 1.7M | 1.71M | 4.73M |
| Long-term Investments | 0 | 7.39M | 23.43M | 24.57M | 0 |
| Tax Assets | 0 | 0 | 4.7M | 5.62M | 6.87M |
| Other Non-current Assets | 472K | 7.48M | 5.72M | 3.03M | 27.43M |
| Total Non-current Assets | 4.19M | 35.1M | 59.32M | 60.62M | 63.76M |
| Total Assets | 55.66M | 84.75M | 116.54M | 125.41M | 166.13M |
| Account Payables | 6.42M | 122K | 355K | 108K | 124K |
| Short-term Debt | 1.98M | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 5.05M | 2.83M | 2.94M |
| Deferred Revenue | 230K | 0 | 79K | 156K | 111K |
| Other Current Liabilities | 4.07M | 4.86M | 648K | 5.7M | 2.67M |
| Total Current Liabilities | 14.17M | 12.24M | 20.05M | 19.52M | 18.29M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 213K | 928K | 852K |
| Other Non-current Liabilities | 0 | 173K | 82.13M | 5.68M | 4.41M |
| Total Non-current Liabilities | 408K | 294K | 82.54M | 7.49M | 5.56M |
| Total Liabilities | 14.57M | 12.54M | 102.59M | 27M | 23.85M |
| Common Stock | 31K | 64K | 77K | 86K | 91 |
| Retained Earnings | (402.69M) | 10.06M | (85.54M) | (73.45M) | (68.43M) |
| Accumulated OCI | 40.23M | (392K) | 1.45M | 501K | 2.32M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 90.91K |
| Minority Interest | 0 | 29.7M | 29.78M | 35.08M | 36.25M |
| Total Equity | 41.09M | 72.22M | 13.95M | 98.4M | 142.28M |
| Total Debt | 2.39M | 613K | 409K | 1.6M | 939K |
| Net Debt | (41.96M) | (24.56M) | (33.1M) | (10.22M) | (36.13M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $37.5M |
| Short-term Investments | $12.3M |
| Receivables | $22.8M |
| Inventory | $11.4M |
| Other Current | $7.8M |
| Total Current Assets | $91.7M |
| PP&E (Net) | $23.6M |
| Intangible Assets | $4.6M |
| Long-term Investments | $31.0M |
| Tax Assets | $7.7M |
| Other Non-current | $3.3M |
| Total Non-current Assets | $70.3M |
| Total Assets | $162.0M |
Analysis
Selected assets total $162.0M for Latest. The largest visible component is Cash & Equivalents at $37.5M, about 23.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 8-K | Current report | Oct 22, 2026 | |
| 8-K | Current report | Sep 1, 2026 | |
| S-8 | S-8 filing | Aug 27, 2026 |
How much cash does GYRE have?
Gyre Therapeutics, Inc. (GYRE) reported $37.07M in cash and equivalents in fiscal 2025.
How much debt does GYRE carry?
Gyre Therapeutics, Inc. (GYRE) reported $939,000.00 of total debt, with net debt of -$36.13M.
Continue the stock analysis
Jump to another research area for this company.